Why Celcuity’s FDA priority review for gedatolisib could reset the breast cancer playbook
Celcuity earns FDA priority review for gedatolisib in advanced breast cancer. Find out what the July 2026 PDUFA date means for its market trajectory. Read More
No fridge, no problem: Stablepharma and AFT join forces to make critical drugs shelf-stable
Stablepharma and AFT team up to develop fridge-free cancer and infection drugs. Find out how this could reshape pharma logistics and global access. Read More
Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment. Read More
Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline
Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology. Read More
Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough?
Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect. Read More
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now. Read More
Accuray (NASDAQ: ARAY) cuts 15% of workforce in $25m transformation plan
Accuray is cutting 15% of its workforce in a $25M restructuring. Find out how this move could reshape its margins, operations, and investor outlook. Read More
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care. Read More
Glenmark’s U.S. launch of Leucovorin Calcium for Injection: A strategic play in the generics arena
Find out how Glenmark Pharmaceuticals’ latest U.S. launch could reshape hospital generics in 2025. Will this move boost its global strategy? Read More
Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings
Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update. Read More